Stonehage Fleming Financial Services Holdings Ltd Cuts Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Stonehage Fleming Financial Services Holdings Ltd reduced its position in Thermo Fisher Scientific Inc. by 85.8% in Q2, owning only 236 shares after selling 1,421 shares, valued at $96,000.
• CEO Marc N. Casper sold 10,000 shares of the company at an average price of $500.96, resulting in a 7.99% decrease in his holdings.
• Analysts have varied new price targets for Thermo Fisher, with JPMorgan Chase & Co. raising their target from $600.00 to $650.00 and maintaining an "overweight" rating.

Stonehage Fleming Financial Services Holdings Ltd reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 85.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 236 shares of the medical research company's stock after selling 1,421 shares during the quarter. Stonehage Fleming Financial Services Holdings Ltd's holdings in Thermo Fisher Scientific were worth $96,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. Nuveen LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter worth about $532,360,000. EdgePoint Investment Group Inc. purchased a new stake in Thermo Fisher Scientific during the 1st quarter valued at about $172,139,000. Cohen Investment Advisors LLC boosted its holdings in Thermo Fisher Scientific by 6,655.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after acquiring an additional 331,180 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after acquiring an additional 329,974 shares during the period. Finally, Auto Owners Insurance Co boosted its holdings in Thermo Fisher Scientific by 6,773.5% during the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company's stock valued at $143,309,000 after acquiring an additional 283,810 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,066 shares of company stock valued at $14,182,963. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 1.8%

Shares of NYSE:TMO opened at $524.95 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The firm has a market capitalization of $198.23 billion, a P/E ratio of 30.36, a P/E/G ratio of 2.85 and a beta of 0.77. The stock has a 50 day moving average price of $488.68 and a 200-day moving average price of $447.94. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the company earned $5.37 EPS. The business's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. HSBC restated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. JPMorgan Chase & Co. increased their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a report on Thursday. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Finally, Wells Fargo & Company dropped their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $593.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.